COVID-19 Pandemic: Update, Successes and Challenges
Wafaa El-Sadr, MD, MPH, MPA
University Professor,
Dr. Mathilde Krim-amfAR Chair of Global Health
Epidemiology (In ICAP)
Director, ICAP, New York, NY
Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc. Copyright © 2020. All rights reserved.
Wafaa El-Sadr, MD, MPH, MPA is the founder and director of ICAP at Columbia University, University Professor of Epidemiology and Medicine, and Mathilde Krim-amfAR Professor of Global Health at Columbia University.
Through ICAP at Columbia University, the Center she founded and directs, she leads a team of 1800 individuals working in more than 30 countries, including in the US. ICAP designs and implements programs for research, education, training, and practice in more than 30 countries around the world. Her focus in on confronting major public health challenges including HIV, tuberculosis, malaria, maternal and child health, non-communicable diseases among others in partnership with in-country stakeholders.
Dr. El-Sadr is a principal investigator of the NIH-funded HIV Prevention Trials Network and has led other studies involving epidemiologic, behavioral, clinical, and implementation research. She has published more than 400 papers.
Dr. El-Sadr received her medical degree from Cairo University, a masters in public health (epidemiology) from Columbia’s Mailman School of Public Health, and a masters in public administration from Harvard University’s Kennedy School of Government. She was named as McArthur fellow in 2008, is a member of the National Academy of Medicine and a fellow of the African Academy of Sciences.
At the completion of this educational session, learners will:
- Be informed of the current epidemiological trends of COVID-19 in NYC and the US.
- Understand the successful aspects of the response and how key milestones were reached.
- Be able to describe the remaining challenges to responding to the pandemic in NYC and the US.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare
Download Article PDF/Slides